All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Pfizer shares were rising early Tuesday after the company reported fourth-quarter earnings and revenue that came in ahead of ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 ...

Pfizer expects to sufficiently de-lever its balance sheet ... the potential to return capital to shareholders through share repurchases. Fourth-quarter 2024 Comirnaty (1) revenues of $3.4 billion ...

(Reuters) -Drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Thursday, boosted by cost-cutting, a ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...

Revenue from COVID vaccine Comirnaty brought in sales of $3.38 billion, while antiviral treatment Paxlovid was $727 million for the quarter. Pfizer makes the Comirnaty vaccine with German partner ...

Despite a significant year-over-year decline in Comirnaty revenue, the overall performance was strong, driven by growth in non-COVID-19 products and strategic acquisitions. Source: Pfizer.